8-K: Alphatec Soars: Q3 Revenue Up 30%, Full-Year Guidance Raised

Alphatec Holdings, Inc. announced strong third-quarter 2025 financial results, with total revenue growing 30% and a significant increase in full-year revenue and profitability guidance.

Summary

• Total revenue for Q3 2025 increased by 30% to $197 million.
• Surgical revenue grew 31% to $177 million, and EOS revenue grew 29% year-over-year to $20 million.
• Achieved 26% growth in net new surgeon users, a key leading indicator of future growth.
• Adjusted EBITDA reached $26 million, expanding by 840 basis points year-over-year, with a 13% margin.
• Generated $5 million in free cash flow for the quarter and is free cash flow positive for the trailing twelve months.
• Full-year 2025 total revenue guidance was raised to $760 million (24% growth), up from $742 million.
• Full-year 2025 non-GAAP adjusted EBITDA guidance was raised to $91 million, up from $83 million.
• GAAP net loss improved to ($29) million from ($39.6) million in Q3 2024.
• Non-GAAP net income was $4 million, a significant improvement from a ($10.6) million loss in Q3 2024.

Sentiment

Score: 9

Explanation: The company reported strong revenue growth, significant improvement in profitability (non-GAAP net income turned positive), substantial Adjusted EBITDA expansion, and raised its full-year guidance for both revenue and Adjusted EBITDA. These are all highly positive indicators of operational strength and future prospects.

Positives

• Total revenue grew by $46 million or 30% to $197 million in Q3 2025.
• Surgical revenue increased by 31% to $177 million.
• EOS revenue grew by 29% year-over-year to $20 million.
• Achieved 26% growth in net new surgeon users, indicating future growth potential.
• Adjusted EBITDA reached $26 million, representing a 13% margin and an 840 basis point expansion year-over-year.
• Generated $5 million in free cash flow in the quarter and is free cash flow positive for the trailing twelve months.
• Full-year 2025 total revenue guidance was raised to $760 million (24% growth), an increase from the previous expectation of $742 million.
• Full-year 2025 non-GAAP adjusted EBITDA guidance was raised to $91 million, up from the previous expectation of $83 million.
• GAAP net loss improved from ($39.6) million in Q3 2024 to ($29) million in Q3 2025.
• Non-GAAP net income turned positive at $4 million in Q3 2025, compared to a ($10.6) million loss in Q3 2024.

Negatives

• Reported a GAAP net loss of ($29) million for the third quarter of 2025.
• Reported a GAAP operating loss of ($15.9) million for the third quarter of 2025.

Risks

• Uncertainty of success in developing new products or products currently in the pipeline.
• Uncertainties in the ability to execute upon the strategic operating plan.
• Uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products.
• Failure to achieve acceptance of products by the surgeon community.
• Failure to obtain FDA or other regulatory clearance or unexpected or prolonged delays in the process.
• Dependence on the continuation of favorable third-party reimbursement.
• Unanticipated expenses or liabilities or other adverse events affecting cash flow or the ability to achieve profitability.
• Uncertainty of additional funding and the form of such funding.
• Product liability exposure.
• Potential for an unsuccessful outcome in any litigation.
• Risk of patent infringement claims.
• Claims related to intellectual property.
• Ability to meet financial obligations.

Future Outlook

Alphatec Holdings, Inc. has raised its full-year 2025 financial guidance, now expecting total revenue to grow 24% to $760 million, up from the previous expectation of $742 million. This includes surgical revenue of $684 million and EOS revenue of $76 million. The company also increased its non-GAAP adjusted EBITDA expectation to approximately $91 million, compared to the previous expectation of $83 million, reflecting confidence in continued profitable growth.

Management Comments

• "I'm proud of the entire ATEC team for delivering another quarter of industry-leading results."
• "Our singular focus on spine is compelling an ever-growing number of surgeons to say yes to ATEC."
• "By integrating data and informatics into our procedural solutions, we are indisputably making spine care better."
• "We are now delivering durable, profitable revenue growth that is generating cash flow."
• "As spine's most relentless, deeply committed stewards, we are uniquely positioned to set the industry standard for years to come."

Industry Context

Alphatec's strong performance, particularly the 30% revenue growth and significant adjusted EBITDA expansion, indicates robust demand within the spine surgery market. The company's focus on integrating data and informatics into procedural solutions, as highlighted by management, aligns with broader industry trends towards technology-driven, personalized medicine and improved surgical outcomes. The growth in net new surgeon users suggests successful market penetration and adoption of its innovative solutions, potentially positioning Alphatec as a leader in a competitive medical device sector.

Comparison to Industry Standards

• Management states the company is "delivering another quarter of industry-leading results" and is "uniquely positioned to set the industry standard for years to come."
• The 30% total revenue growth and 31% surgical revenue growth are strong indicators compared to typical single-digit or low double-digit growth rates seen in many established medical device segments.
• The 840 basis point year-over-year expansion in Adjusted EBITDA margin to 13% demonstrates significant operational leverage and efficiency gains, which is a positive trend often sought after by investors in the medical technology space.
• The 26% growth in net new surgeon users suggests a strong competitive position and successful surgeon adoption, which is a key metric for growth in the medical device industry.

Legal Proceedings

• The company is involved in various litigation matters, including patent litigation and other matters related to its business transformation started in 2018, which are excluded from non-GAAP financial measures.
• Risks include an unsuccessful outcome in any litigation and patent infringement claims.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, raised guidance, and improved profitability, potentially leading to increased share value.
• Surgeons/Customers: Increased adoption of PTP and LTPTMEOS solutions and 26% growth in net new surgeon users indicate positive reception and value from the company's innovative solutions.
• Employees: Continued growth and strong performance suggest job stability and potential for growth opportunities within the company.
• Creditors: Improved financial health, positive free cash flow, and increased EBITDA guidance enhance the company's ability to meet its financial obligations.

Next Steps

• A live webcast of the financial results will be held today, October 30, 2025, at 1:30 p.m. PT / 4:30 p.m. ET.
• A replay of the webcast will be available through the Investor Relations section of ATEC's corporate website for twelve months.
• The company will continue to execute its strategy focused on spine surgery, integrating data and informatics into procedural solutions.

Key Dates

Recommendation

The filing demonstrates exceptional operational and financial performance, with significant revenue growth, a positive shift to non-GAAP net income, and substantial Adjusted EBITDA expansion. The decision to raise full-year guidance for both revenue and profitability signals strong management confidence and positive momentum. The growth in net new surgeon users is a key leading indicator for sustained future growth. These factors collectively suggest a robust and improving business trajectory, making the stock highly attractive for investment.

Keywords

Alphatec Holdings, ATEC, Spine Surgery, Medical Devices, Financial Results, Q3 2025, Revenue Growth, EBITDA, Guidance Increase, Orthopedics, Surgical Solutions, EOS Imaging, PTP, LTP